Ciaramella Giuseppe 4

What Happened
Giuseppe Ciaramella, President of Beam Therapeutics (BEAM), sold 11,810 shares of common stock on April 1, 2026 at $24.58 per share, generating proceeds of $290,290. The transaction is a sale (S) and was executed to satisfy tax withholding obligations tied to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and price: April 1, 2026 — 11,810 shares at $24.58 each; total $290,290.
• Reason/footnote: Shares were automatically sold to cover tax withholding on RSUs granted under Beam’s 2019 Equity Incentive Plan (vesting dates Mar 31 of 2022, 2023, 2024 and 2025). Sales were effected pursuant to a Rule 10b5-1 trading plan adopted May 23, 2023 (footnote F1).
• Transaction code: S (Sale); tax-withholding disposition.
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4 — see the full filing for current holdings.
• Filing timeliness: Form 4 filed Apr 6, 2026, which appears later than the typical 2-business-day filing requirement for insider transactions.

Context
Sales executed solely to cover tax withholding on RSU vesting are common and generally considered routine rather than a direct signal about an insider’s view on the company’s prospects. Trades under pre-established Rule 10b5-1 plans help demonstrate the transactions were non-discretionary and scheduled in advance. For investment decisions, purchases by insiders tend to carry more weight than routine withholding sales.